Alnylam (ALNY) is well on its way to having its third commercial product before the end of 2020. A prior release
of positive top-line data from the company's pivotal ILLUMINATE-A study
of lumasiran already indicated approvable efficacy, but the full data
presented on Sunday June 7 added some valuable context to what should be
a worthwhile commercial opportunity for the company.
As I indicated in my last article
on Alnylam, I still regard this stock as a long-term holding in my
portfolio, but I wasn't as excited about the near-term price performance
potential in early May. With the shares down about 10% since then, the
opportunity is more interesting now, though I have some modest
"strategic" concerns that the strong rally in biotech relative to the
S&P could leave the sector more vulnerable to near-term
profit-taking as investors regain confidence in a stronger/quicker
post-Covid-19 economic recovery.
Click here to continue:
Clinical Data Reaffirm That Lumasiran Will Almost Certainly Be Alnylam's Third Commercial Product
No comments:
Post a Comment